Sutro Biopharma Q2 2024 Earnings Report

Sutro Biopharma EPS Results

• Actual EPS: -$5.90
• Consensus EPS: -$7.90
• Beat/Miss: Beat by +$2.00
• One Year Ago EPS: N/A

Sutro Biopharma Revenue Results

• Actual Revenue: $25.71 million
• Expected Revenue: $26.28 million
• Beat/Miss: Missed by -$570.00 thousand
• YoY Revenue Growth: N/A

Sutro Biopharma Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: TAS
• Conference Call Date: Tuesday, August 13, 2024
• Conference Call Time: 4:00PM ET

Sutro Biopharma (NASDAQ:STRO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas.

With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.